Figure S1. Calibration curve analysis of the nomograms in the training dataset. (A) Haloperidol. (B) Olanzapine. (C) Paroxetine. (D) Mirtazapine/venlafaxine. (E) Oxazepam/lorazepam.



Figure S2. Calibration curve analysis of the nomograms in the validation dataset. (A) Haloperidol. (B) Olanzapine. (C) Paroxetine. (D) Mirtazapine/venlafaxine. (E) Oxazepam/lorazepam.



Figure S3. Decision curve analysis of the nomograms in the training and validation datasets. (A) Haloperidol. (B) Olanzapine. (C) Paroxetine. (D) Mirtazapine/venlafaxine. (E) Oxazepam/lorazepam.